Contents - pharmaphorum

Editions

Contact

1. Cover
2. Introduction
3. Contents
4. LEO Pharma's new research lead on driving agility
5. The information challenge of rare disease diagnosis
6. Sign-up for pharma news alerts
7. Inside the UK’s leading efforts to restart research
8. Centessa founder on the company’s unique R&D model
9. The invisible burden of rare diseases
10. Digitalising drug discovery
11. Podcast
12. The landscape for UK SMEs post-COVID
13. The post-COVID face of pharma research
14. FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines
15. Subscribe to future Deep Dive issues
16. Contact the Deep Dive team

Open magazine

Editions

Contact

Hi there!

Click here and sign up now

Contents: Research and Development 2021

Cover

Click here

Introduction

Welcome from the Editor

Click here

LEO Pharma’s new R&D lead on driving agility

After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global R&D. We spoke to him about the lessons he’s taking from his prior jobs and what it means to be an R&D leader in the modern industry.

Click here

Solving the “information challenge” of rare disease diagnosis

We take a look at efforts from charities, the government and digital innovators to boost awareness of rare conditions among GPs and make the clinical pathway smoother for patients.

Click here

The pharma world at your fingertips

Daily News from pharmaphorum – insights and analysis on the big trends shaping healthcare and the pharmaceutical industry

Click here

Inside the UK’s leading efforts to restart clinical research

A herculean national effort has seen 69% of studies paused due to COVID restart under the NIHR’s Restart Framework. Experts from the institute tell us how lessons learned from the sector-wide collaboration will change UK research forever.

Click here

Centessa’s founder on the new company’s unique R&D model

Putting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted – but that’s what biotech investment guru Francesco de Rubertis has achieved with his latest project Centessa.

Click here

Focus on Rare: the invisible burden of rare diseases

Emma Sutcliffe from NexGen Healthcare Communications looks at how patient insights can bring the invisible challenges of living with a rare condition into plain view.

Click here

Digitalising drug discovery

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford.

Click here

Podcast

Listen to discussions of key industry trends with leading pharma figures

Click here

The landscape for UK SMEs post-COVID

Big pharma might have dominated COVID headlines, but behind the scenes an army of SMEs has allowed the UK to respond swiftly to the pandemic. We take a look at why new infrastructures are vital to the sector’s future.

Click here

The post-COVID face of pharma research and development

The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response to some long-standing issues with the clinical trials process.

Click here

FUJIFILM Irvine Scientific’s COO on cell therapy, COVID vaccines and 50 years of the company

From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become one of the top manufacturers of cell culture media.

Click here

Forthcoming issues of Deep Dive

Sign up to receive complimentary editions of the magazine direct to your inbox, including the forthcoming Market Access issue

Click here

Deep Dive – contact us

How to get in touch with the magazine’s editorial, commercial and design teams

Click here